EpiEP, Inc.

What we've been up to

EpiEP, Inc. is a medical device company that has developed an FDA cleared and CE marked epicardial access system, EpiAccess™. This system engages a patent protected pressure-guided needle that is designed to alert physicians of needle tip location during epicardial access procedures.

Entering the pericardial space with a minimally invasive technique is considered the “final frontier” for electrophysiology procedures. EpiEP has devoted itself to developing a specialized instrument that will facilitate an epicardial approach for patients who will benefit from minimally invasive procedures on the surface of the heart.

Learn More

Our Mission

An epicardial approach allows the physician to work on the outside surface of the heart muscle rather than on the inside of the heart. While several companies have emerged with epicardial tools for treatment of ventricular tachycardia (VT), atrial fibrillation (AF), and left atrial appendage (LAA) ligation, EpiEP's solution uniquely employs a pressure guided needle in conjunction with standard of care fluoroscopy to provide the physician with safe, precise, real-time guidance confirming access into the pericardial cavity.

During pre-clinical and clinical trials, physicians have expressed satisfaction with the performance of the EpiAccess™ System and its unique ability to display adjunctive data, designed to permit the physician to recognize when the needle tip reaches the pericardial space. This is a technology platform that can be calibrated for other anatomic locations within the body, but to date our focus has been the development and commercialization of the EpiAccess™ System to provide pressure guided access to the pericardial space.


  • May 2015
    Completed EASe Post-Market Clinical Study
  • October 2014
    FDA 510(k) clearance for EpiAccess™ System
  • August 2014
    FDA submission completed
  • March 2014
    EpiAccess™ System CE Marked
  • 2013 - 2014
    Multi-center clinical trial in Europe
    (Prague, Czech Republic; Milan, Italy; Coimbra, Portugal; Bordeaux, France)
  • December 2013
    EpiEP receives ISO 13485 Certification
  • 2012
    Feasibility study completed in Europe
    (Prague, Czech Republic; Debrecen, Hungary)
  • May 2012
    Findings from pre-clinical trial presented at Heart Rhythm Society meeting
    Boston, MA
  • May 2011
    Pre-clinical trial at Mayo Clinic
    Rochester, MN
  • 2010
    First product design
  • December 2008
    Company formed

Management Team

Creating a better future

Pamela Bunes

Chief Executive Officer, Founder

Ms. Bunes has 24 years of medical device history including numerous years with Johnson & Johnson’s Ethicon Endo–Surgery and Biosense Webster, followed by nine years as the senior executive of two start-up companies, one which was a public entity. In 2013 she was a member of the FDA entrepreneur in residence team and currently serves on the operating board of directors for the Yale Entrepreneurial Institute.

Her experience includes sales and sales management, marketing, execution of new product launches, achieving both FDA and CE Mark approval for commercializing new medical technologies, and forming strategic partnerships and alliances through licensing or acquisitions. During the last decade, her market focus has been cardiology and electrophysiology.

She is experienced in raising capital for both private and public companies, and developing innovative medical technologies that improve patient’s lives. Ms. Bunes strives to find a collaborative balance with her team and board of directors, believing that the collective genius of the experience supporting her vision improves the chances of a successful outcome for patients, physicians, and investors.

Colin M. Rolph

Chief Financial Officer

Mr. Rolph has been an angel investor in several start-ups over the past fifteen years. For the past 10 years, Mr. Rolph has been running day to day operations of Tall Oaks Capital, LP and has been CFO of the fund for the past 7 years. Mr. Rolph has also been the CFO of EpiEP, Inc. for the past 3 years and part time CFO of iTiHealth, a start-up out of the University of Virginia for the past two years.

Starting in April of 2014 he is the acting CFO of another start-up out of the University of Virginia, TearSolutions, LLC. Mr. Rolph graduated from the Rochester Institute of Technology in 1982 with a Bachelor of Science.

Michael Theran

VP of Product Development

Mr. Michael Theran is the Vice President of Product Development at EpiEP, Inc. He received his Bachelor of Science in Mechanical Engineering from Boston University.

After starting his career in consumer products as a product designer, product manager then engineering executive, Mr. Theran decided to focus on start-up companies in the life sciences including medical devices. Creating much needed and highly innovative new medical devices from university research has been Mr. Theran’s focus for the last 10 years.

Elsa Abruzzo, RAC, FRAPS

Regulatory Consultant

Elsa has a 25+ year successful regulatory, quality, clinical, and operations track record. Most recently as Founder and CEO of Cygnus Regulatory, her areas of expertise include cardiovascular, neurovascular, orthopedic, CRM, diagnostic imaging, mHealth, Health IT, and point of care diagnostics. Elsa successfully headed numerous project teams at a variety of start-ups. Prior to Cygnus, Ms. Abruzzo worked at companies such as Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies (acquired by Edwards LifeSciences), AtriCure, and Polymer Technology Systems Cardiochek.

Ms. Abruzzo’s regulatory and clinical strategies have resulted in global commercialization of numerous technologies. Some of the disruptive medical solutions Elsa helped bring to market include: transcatheter tissue heart valves, implantable biomaterials, surgical adhesives, embolic agents, stents, atrial fibrillation ablation devices, neuromodulation devices, and point of care analyzers.

Ms. Abruzzo has a B.S. in engineering from the University of Miami (Coral Gables, FL), is regulatory affairs certified (RAC), and a Fellow of the Regulatory Affairs Professional Society (FRAPS). As a thought leader in regulatory, she has been invited to present nationally and was recognized for leadership in Regulatory and Quality by MDDI Magazine 2007.


Q.S. Management

NOVUS Management Group is a technology-startup consulting group that specializes in quality assurance, patent protection, marketing, and software development for the medical device industry. Founded in 2010 by Scott D. Wampler, NOVUS Management Group assists early-stage medical device companies in bringing their products to market by supplying all stages of technology development, patent prosecution, quality control, regulatory support and marketing consultation.

In addition Novus has a dedicated software engineering team to conduct UI/UX GUI design as well as full software development and validation. Based in Cincinnati, Ohio, NOVUS Management Group LLC has assisted over 12 clients through 2013.

Board of Directors

Our industry veterans

Jonathan Mark Sackier MD, MB, ChB, FRCS, FACS

Dr. Sackier has 30 years of healthcare experience. Trained in Britain as a surgeon and recruited to the USA in 1989 he helped lead the laparoscopic surgery revolution. As a Professor at George Washington University in Washington, DC, he founded, and funded the Washington Institute of Surgical Endoscopy, a center for education, research & innovation. He is an Adjunct Professor of Surgery at the University of Virginia and his activities in basic and clinical research funded by multiple grants have led to many publications, chapters and books.

Dr. Sackier’s collaborations with the pharmaceutical and medical device industry have led to multiple technologies coming to market with partners like Valleylab, Pfizer, Karl Storz, Applied Medical & Pall. In 1984 his team at Genethics, a company he founded, discovered and patented amniotic stem cells and licensed the rights to a publicly traded British drug discovery company. He helped develop and market the AESOP robot with Computer Motion, who had a successful IPO in 1997 and has also built a research & product design company, a medical contract sales organization, a locum agency and helped found a communications company. He has consulted to healthcare companies and worked with the financial community on enterprise financing and due diligence.

Dr. Sackier has served the Steppenwolf Foundation, is a Trustee of First Star, on the Board of the American College of Surgeons Foundation, the Surgical Fellowships Foundation and chaired the Board of the Larry King Cardiac Foundation. He has sat on the Associate Board of AdvaMed and several corporate governance and scientific advisory boards. He was until recently Chairman of Adenosine Therapeutics and among others, sits on the Board of Clinvue, Hemoshear and Rex Bionics.

Mary Lake Polan, MD, PhD, MPH

Dr. Polan served as the chair of the Department of Obstetrics and Gynecology at Stanford University School of Medicine for over 15 years, and is currently an Adjunct Professor, Department of Obstetrics and Gynecology and Reproductive Sciences at Columbia University School of Medicine.

Dr. Polan served on the board of Wyeth Pharmaceuticals prior to it’s acquisition by Pfizer and currently serves on the board of Quidel Corp, San Diego, CA as well as on the boards of several privately held life sciences companies. She is also a Managing Director of Golden Seeds, an angel investing group which invests in women led companies. In addition, she chairs an SAB in Women’s Health for Proctor and Gamble.

Dr. Polan’s research has involved ovarian and urologic function with many publications in both areas. She is a member of the Institute of Medicine of the National Academy of Sciences and has served on a number of NIH and university committees. She has a long-standing interest in women’s health research and has been actively involved in international public health. She initiated The Eritrean Women’s Project in 2001 and has maintained this surgical project in Eritrea to repair fistulas resulting from traumatic births.

She received her bachelor’s degree from Connecticut College and her Ph.D. in Molecular Biophysics and Biochemistry and M.D. from Yale University and completed her residency and Reproductive Endocrine Fellowship in the Department of Obstetrics and Gynecology at the Yale University School of Medicine. Dr. Polan received her M.P.H. (Maternal and Child Health Program) from the University of California, Berkeley.

Konstantine Drakonakis, Director, Launch Capital

Konstantine is an experienced early stage investor focused on proprietary technologies in the tri-state NY region. As an "Entrepreneurial Engineer", Konstantine gravitates to technology companies within the software, med-tech and green-tech markets. He holds a Masters in Environmental Management from Yale University and a Civil and Environmental Engineering degree from the University of Vermont.

He is a board certified Professional Engineer and is a member of the National Civil Engineering Honors Society. Konstantine lives in New Haven with his wife, 3 year old son and new baby girl. When he can, he finds a Zen moment in his garden.

Thomas K. Brooks

Tom started his medical career at Ethicon Endo Surgery in Sales and moved up into Sales Management in the New York area. He moved to a startup, Meditech, known today as Boston Scientific and held positions in Sales, Sales Management and Business Development.

A few years after the company went public, he left to move to Atlanta as employee number 7 at Novoste Corporation, which went public in 1996. In 2001, Tom moved out to Menlo Park, California to become the President of Conor Medsystems who was developing a novel drug eluding coronary stent and raised over $30 million in capital.

The Company went public in 2004 and was sold to Johnson & Johnson in 2007 for $1.4 billion. In 2003, he formed a venture capital fund, Healthcare Capital Partners, whose primary focus was making seed and early-stage investments in medical device companies.

In 2009 he went back to the west coast to run Mast BioSurgery in San Diego. He returned to Atlanta 2013 and is working on his next start-up company, Vein Closure Systems based in Georgia.

Russell Tweedale

Russell has invested in more than 50 companies during his tenure as Managing Director of Investments at Connecticut Innovations. He has led CI’s investments in bioscience companies including Affomix Corporation, Cardiopulmonary Corporation, Genaissance Pharmaceuticals, Ipsogen and Metagenomix, Inc. Russell has also led CI’s investments in I-Mark and LiveClips, and serves on a number of boards.

Seven of the current or former CI portfolio companies that Russell has worked with have had successful initial public offerings. Russell has considerable experience in economic and venture analysis, engineering cost accounting, systems analysis, scientific and commercial programming, math analysis, EDP auditing and computer modeling.

He was previously with United Technologies Corp., Wolf Research and Development, Scientific Leasing and the Robert E. Nolan Co. Russell holds a B.S. in Electrical Engineering and an M.B.A. from the University of Hartford.

Don Crawford

Don is President and Chief Executive Officer of Analytics for Life, Inc. He previously founded and led medical device company Sapheon Inc. from inception to $238M acquisition by Covidien in 2014. His career started with Medtronic and included positions with Guidant, Ventritex, and Intermedics.

Don received his degree in chemical engineering from Georgia Tech and MBA from Emory University.

Scientific Advisors & Investigators

Our Medical Experts

Principle Investigator and Scientific Advisor

Andrea Natale, MD

FACC, FHRS, FESC, Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Austin, Texas

Scientific Advisors

Vivek Reddy, MD

Mount Sinai School of Medicine, Mount Sinai Hospital, New York, New York, Director of Cardiac Arrhythmia Services, Professor of Medicine, Cardiology, The Leona M. and Harry B Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology

Mitchell Krucoff, MD

Duke University Medical Center, Durham, NC, Duke Clinical Research Organization,Co-Director, Cardiovascular Devices Group Director, Electrocardiology Core Lab, Professor of Medicine, Cardiology

Moussa Mansour, MD

Director of Cardiac Electrophysiology Laboratory, Mass General Hospital; Director Atrial Fibrillation Program, Mass General Hospital; Assistant Professor of Medicine, Harvard Medical School

Mauricio Scanavacca, MD

InCor, University of São Paulo, Professor of Medicine, São Paulo University Medical School and supervisor of the Electrophysiology Lab

Clinical Investigators

Petr Neužil, MD

Na Holmolce Hospital, Prague, Czech Republic

David Burkhardt, MD

St. David’s Medical Center, Austin, Texas

Luigi Di Biase, MD, PhD

Montefiore Medical Center, New York, New York

Zoltan Csansadi, MD

University of Debrecen, Debrecen, Hungary

Claudio Tondo, MD

Centro Cardiologico Monzino, Milan, Italy

Coronado Carrbucchio, MD

Centro Cardiologico Monzino, Milan, Italy

Antonio Dello Russo, MD

Centro Cardiologico Monzino, Milan, Italy

Miguel Ventura, MD

IdealMed Unidade Hospitalar de Coimbra, Coimbra, Portugal

Douglas Packer, MD

Mayo Clinic, Rochester, Minnesota

Matthew Swale, MD

Mayo Clinic, Rochester, Minnesota

Frédéric Sacher

Hôpital Haut-Lévêque, Bordeaux, France

Pierre Jaïs, MD

Hôpital Haut-Lévêque, Bordeaux, France


Introducing the The EpiAccess™ System

The real-time guidance and confirmation capability of the EpiAccess™ system are based on both disposable and hardware components. The disposable is an access needle that is used to provide single-use access to the pericardial cavity; the capital component contains the host computer and relevant algorithms.

FDA 510(k) clearance & CE Mark approval have been granted.

The EpiAccess™ Needle

The system includes a proprietary, tuohy-style needle with a fiber optic pressure sensor mounted permanently at the distal tip. The real-time pressure signal in combination with standard of care fluoroscopy is designed to provide the physician position guidance and needle tip position confirmation.

EpiAccess™ “SMART” Needle pictured during epicardial access.

Product being used as part of the EASe Clinical trial conducted in Europe.

Real-Time Feedback

Our instrumentation captures the pressure signal from the sensor and displays the signals on a monitor. The graphical user interface is easy to read, allowing physicians to understand the real-time pressure waveform intuitively.

The data provides guidance to the physician on the position of the needle so they can know when the needle has reached the desired location. The needle tip pressure wave form is designed to confirm access to the pericardial space.

EpiAccess™ screen capture showing typical pericardial signal.

The Control Unit

The control unit is designed to be easy to use, flexible and durable. Data capture equipment and a touch screen monitor are housed in a mobile cart that allows the user to position the system as desired.

Its design features allow quick and convenient transition from a “Secured” mode for storage to “Procedure Ready” mode. When in “Secured” mode, the control unit is more protected.

The control unit can be used as a stand alone monitor or integrated into most existing monitors; see below.

Stand Alone

The EpiAccess™ unit can be used as a stand alone device, as shown above. The monitor can be conveniently rolled into place and raised or lowered to the clinicians preferred position, typically adjacent to the fluoroscopy monitor.

Integrated System

The EpiAccess™ system can also connect to other monitors, such as a monitor within a monitor bank. Many clinicians prefer to position the EpiAccess™ system display adjacent to the fluoroscopy monitor, as shown above.

Product being used as part of the EASe Clinical trial conducted in Europe.


Everyone needs great partners

KLP Ventures

Private Investors

Contact us

Fill out the form below and we'll get in touch


142 Temple Street Suite 206
New Haven, CT 06510 USA


The latest from EpiEP

EpiEP, Inc. Appoints Don Crawford to Board of Directors

Medical device veteran and executive joins EpiEP, Inc. board of directors

New Haven, Conn., May 11, 2015 – EpiEP Inc. (EpiEP), a medical device company that has developed an FDA-cleared and CE-marked epicardial access system, today announced that Don Crawford, president and chief executive officer of Analytics For Life (A4L), has joined the EpiEP, Inc. board of directors.

Crawford has been a thought leader in the medical device field for more than 30 years focusing primarily on Cardiac Rhythm Management (CRM) products for electrophysiologists.

In his board role, he will participate in meetings with EpiEP, Inc. at the upcoming Heart Rhythm Society meeting in Boston, Mass., as EpiEP’s results from its EASe study will be presented in a moderated poster presentation on Friday, May 15, at 3:25 p.m.

“We are excited to add Don to our board as his vast experience lends additional expertise to the already diverse background of the EpiEP, Inc. board of directors and management,” said Pamela Bunes, chief executive officer and founder of EpiEP, Inc. “I have enjoyed working with Don on various projects through the years and know that his addition to the board adds both breadth and depth to our reach in the electrophysiology market.”

Crawford’s most recent executive management role as CEO and founder of Sapheon, Inc., which resulted in a successful exit to Covidien, Inc. and was acquired by Medtronic, Inc. in 2014 as part of its acquisition of Covidien. This transaction resulted in a total exit value of $238 million paid to its investors and shareholders. Prior to his role at Sapheon, Crawford represented Japan’s Lifeline interests in negotiating an asset purchase of Sorin Japan and a 10-year, $1 billion distribution contract agreement with Sorin CRM product lines.

Leading up to this international role with Lifeline, Crawford served as the general manager and member of the board of directors of Intermedics Japan K.K., which is now part of Boston Scientific, Inc.

“I am thrilled to give my support to the great foundation of success that has been achieved here at EpiEP,” said Crawford.

About EpiEP, Inc.

EpiEP, Inc. has licensed a portfolio of patent-protected epicardial medical devices from the University of Virginia. These products will impact the growing field of electrophysiology by providing physicians with novel tools to access and treat various cardiac conditions. The EpiAccess™ system is the flagship product, which provides electrophysiologists with a pressure guided access needle so the physician knows where the tip of the needle is located when it is being advanced to the virtual space between the pericardial sac and the surface of the heart without injuring the heart. The EpiAccess™ system is designed to result in better patient outcomes by reducing unintended puncture in the heart muscle. The system provides real-time feedback for physicians so they can know when the needle has reached the desired location.

Source: EpiEP, Inc.
Pam Bunes
Founder and CEO
+1 864 423 2526
+1 203 779 5383
Investor Relations

EpiEP, Inc. Announces Completion of the EASe Post-Market Clinical Study

Medical device company reaches milestone for FDA-cleared and CE-marked epicardial access system

New Haven, Conn., May 4, 2015 – EpiEP Inc. (EpiEP), a medical device company that has developed an FDA-cleared and CE-marked epicardial access system, today announced the completion of the Post-Market Clinical Follow-up (PMCF) study for the EpiEP EpiAccess™ System (“EASe”), conducted at four sites in Europe.

The EpiAccess™ system provides real-time information on the location of the needle tip during complex epicardial procedures.

“We are delighted to have reached this significant milestone for our organization and would like to thank the physicians and patients that participated in the study,” said Pamela Bunes, founder and CEO at EpiEp. “We plan to continue to monitor the system performance in the coming months with the start of our US - based registry, EASYER.”

Data from the study will be presented at the Heart Rhythm Society annual meeting in Boston, Mass., by Luigi Di Biase MD at the moderated poster session called Catheter Ablation: New approaches and new tools on Friday, May 15, 2015, at 3:25 p.m. in the EpiCenter Theater 2, Exhibit Hall.

The EpiAccess™ system obtained FDA 510(k) clearance on October 29, 2014 (K142245) and has CE Mark approval for sale and distribution in Europe. The system includes a single-use needle with an incorporated pressure sensor, and a pressure monitor that uses proprietary algorithms to analyze pressure frequency data. The information is presented in an intuitive and easy to understand display, which instantly informs physicians of needle tip location which is designed to reduce the risk of procedure complications and to simplify access to the pericardial cavity.

“Together with existing image guidance, EpiAccess provides physicians with additional, detailed needle positioning information to more safely access the pericardial space,” said Andrea Natale MD, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Austin, TX. “We are very excited to see the data from EASe, which will serve to further open up the field of safe, effective pericardial access and related therapies in the pericardial space.”

Source: EpiEP, Inc.
Pam Bunes
Founder and CEO
+1 864 423 2526
+1 203 779 5383
Investor Relations

EpiEP, Inc. Receives FDA 510(k) Clearance for EpiAccess System™

Pressure-guided epicardial access system enables electrophysiologists to perform challenging procedures on the surface of the heart

New Haven, Conn. - Nov. 10, 2014 – EpiEP, Inc. (EpiEP), today announced that its EpiAccess™ system, a pressure-guided epicardial access system designed to help physicians perform procedures on the surface of the heart, has received 510(k) clearance from U.S. Food and Drug Administration (FDA), a step that will allow EpiEP to commercially distribute the device.

EpiEP is a research and development medical device company with a portfolio of innovative epicardial technologies initially targeting minimally-invasive epicardial access for electrophysiology procedures such as ventricular tachycardia (VT), atrial fibrillation (AF), and left atrial appendage occlusion (LAA), which in some instances require access to the surface of the heart.

“This clearance marks a significant advance for EpiEP and our lead product,” said Pamela Bunes, CEO of EpiEP. “The EpiAccess™ system is positioned to immediately impact the growing field of epicardial electrophysiology procedures. We look forward to launching the EpiAccess™ system to full commercialization in the U.S. and providing physicians with a unique device that allows them to access the pericardial space, which surrounds the heart.”

The EpiAccess™ system is the flagship product, which provides electrophysiologists a pressure guided access needle. Pressure guidance allows the physician to know where the needle tip is located when it is advanced under fluoroscopic guidance to the virtual space between the pericardial sac and the surface of the heart without injuring the heart. It was CE Mark (Conformité Européenne) approved for sale in Europe in March 2014, and has been used in a post-market study in Prague, Czech Republic, Milan, Italy, Bordeaux, France, and Coimbra, Portugal.

“Despite the growing importance of epicardial access during ablation procedures, it is recognized that the fear of potential complications has limited the use of an epicardial approach,” said Andrea Natale, M.D., and Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas. “The EpiAccess™ system is the first product designed and approved for use in Europe and FDA 510(k) cleared in the United States that will offer physicians more confidence to use this approach whenever it could be beneficial to the patient.”

Editor’s Note: The EpiAccess™ system is not available for sale or use in all countries. For additional information, please visit www.epiep.com.

Media Contact:
Pamela Bunes
EpiEP, Inc.
Phone: 864-423-2526
Email: pbunes@epiep.com

Pamela Bunes: a Business New Haven Rising Star

October 6, 2011 Congratulations, Pamela Bunes, on being named a Business New Haven Rising Star for 2011! We are proud that New Haven-based EpiEP Inc., the company you founded and now lead, is a member of our Connecticut Innovations portfolio.
Read More »

U.Va. Start-Up EpiEP Receives $1.5 Million Investment

July 8, 2010 — EpiEP Inc., a medical device company spun out of the University of Virginia, has received $1.5 million in investments and commitments for the development of its novel EpiAccess system, which shows promise to improve and expand the treatment of cardiac arrhythmia and other heart conditions.
Read More »

Press Inquiries?


Last Updated: November 8, 2014

This privacy statement ("Privacy Statement"), together with the Terms of Use and other published guidelines, governs any interaction with us at our website at www.epiep.com (the "Site"), including how EpiEP, Inc. ("EpiEP" or “we” or “us”) collects, uses, discloses, transfers or stores personal information that you may provide to us through the Site, including email communications. Please take a moment to get acquainted with our policies and let us know if you have any questions.

We reserve the right to change or modify this Privacy Statement at our sole discretion at any time without prior notice to the users of the Site and your continued use of the Site following the posting of such changes shall mean that you have accepted those changes. When we change the policy in a material way a notice will be posted on our Site along with the updated Privacy Statement.

You are not required to provide any personal information in order to browse the Site and learn more about EpiEP and our company, products and research. However, you may provide information to us through our Site, such as through our “Contact Us” form. This Privacy Statement applies to information that we may collect from you through the Site.

By using the Site or providing any personal information to EpiEP through the Site, you consent to the terms set forth in this Privacy Statement. If you do not agree to the terms of this Privacy Statement, please discontinue your use of this Site and do not provide any personal information to us through the Site.

Collection and Use of Personal Information

EpiEP may collect two types of personal information about users: "personal information" (which may include name, postal address, telephone number, e-mail address and other data) and "aggregate Information" (such as non-identifying and aggregate usage and volume statistical information from visitors to the Site and other information regarding user activities on the Site).

EpiEP collects personal information in order to communicate with you and to provide the information or other services that you have requested. For example, if you request information on our products or research, we may use your personal information in order to respond. EpiEP may also collect and log certain information to help diagnose technical problems, administer and improve the quality of the Site, analyze trends, track user movement around the Site and gather demographic information about the EpiEP Site's user base.

Disclosure to Third Parties

EpiEP uses the personal information provided on or through its Site in accordance with good commercial practices and applicable law. EpiEP does not share, sell or trade your personal information with third parties for marketing or promotional purposes. However, EpiEP may make your personal information available to its strategic partners directly involved in the operation, performance, support and/or maintenance of the Site or fulfilling your request. For example, these companies may help EpiEP process information, deliver email notices and the like, manage and enhance our user data, or provide customer service. These companies are permitted to use the personal information only to provide EpiEP with specific services, and not for any other purposes.

EpiEP may also disclose personal information as required by law, to comply with requests of law enforcement or other government authorities or where EpiEP believes it is necessary or appropriate to protect the safety, rights or property of EpiEP, its employees or others.


EpiEP will maintain commercially reasonable safeguards, including administrative, technical, and physical measures to ensure the security, integrity and privacy of your personal information against loss, theft, and misuse, as well as unauthorized access, disclosure, alteration, and destruction. Notwithstanding the foregoing, no transmission of data over the Internet is guaranteed to be completely secure. It may be possible for third parties not under the control of EpiEP to intercept or access transmissions or private communications unlawfully.

Third-Party Sites

This Site may contain hyperlinks to certain third-party websites. EpiEP is not responsible for the privacy practices or the content of these other websites. Customers and visitors will need to check the policy statement of these other websites to understand their policies. Customers and visitors who access a linked site may be disclosing their private information. It is the responsibility of the user to keep such information private and confidential. We encourage you to review the privacy policies of any third party sites before providing personal information to these sites.

Online Privacy Statement Only

This online Privacy Statement applies only to information collected through the Site and not to information collected offline.

Sale of EpiEP Assets

In the event that all or part of EpiEP is acquired by or merged with a third party entity, your personal information may be included in the assets of EpiEP. You agree that we may transfer or assign the information we have collected from you as part of any such merger, acquisition, or other change of control. In the event of our bankruptcy, insolvency, reorganization, receivership or assignment for the benefit of creditors, you understand and agree that EpiEP may not be able to control how your personal information is treated, transferred or used.

International Users

If you are accessing the Site from the European Union, Asia, or any other region with laws or regulations governing personal data collection, use, and disclosure, that differ from United States laws, please be advised that through your continued use of the Site, which is governed by U.S. law and this Privacy Statement, you are transferring your personal information to the United States and you consent to that transfer and use as set forth in this Privacy Statement and our Terms of Use.


If you have questions about this Privacy Statement, please contact us at info@EpiEP.com.


Last Updated: November 8, 2014


As used on this web site, “EpiEP”, and “the Company” refer to EpiEP, Inc., a Delaware corporation.

Acceptance of Terms

The following are terms of a legal agreement between you and EpiEP. By accessing, browsing and/or using this site (“Site”), you acknowledge that you have read, understood, and agree to be bound by these terms and to comply with all applicable laws and regulations. If you do not agree to these terms, do not use this Site.

Revisions to Terms of Use

EpiEP may at any time revise these Terms of Use by updating this posting. By using this Site, you agree to be bound by any such revisions and should therefore periodically visit this page to determine the then current Terms of Use to which you are bound.

The material provided on this Site is protected by law, including, but not limited to, United States copyright law and international treaties. The copyright in all content and material provided on this Site is held by EpiEP. Except as stated herein, none of the material may be copied, reproduced, distributed, republished, downloaded, displayed, posted or transmitted in any form or by any means, including, but not limited to, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of EpiEP or the copyright owner. Permission is granted to display, copy, distribute and download the materials on this Site for personal, non-commercial use only and subject to the conditions that you do not modify the materials and that you retain all copyright and other proprietary notices contained in the materials. This permission terminates automatically if you breach any of these terms or conditions. Upon termination of the permission granted hereby, you will immediately destroy any downloaded and printed materials. You also may not, without EpiEP's permission, "mirror" any material contained on this Site on any other server. Any unauthorized use of any material contained on this Site may violate copyright laws, trademark laws, the laws of privacy and publicity, and communications regulations and statutes.


The EpiEP name and logo and any other trademarks, service marks or product or service names, marks or logos (the “Trademarks”) are the trademarks of EpiEP, Inc. Nothing on this Site should be construed as granting, by implication, estoppel or otherwise, any license or right to use any Trademark displayed on the Site, without the written permission of EpiEP. Neither the name of EpiEP nor the EpiEP logo may be used in any way, including in advertising or publicity pertaining to distribution of materials on this Site, without prior, written permission.

Company Products

Information regarding the company and products developed by or under development by EpiEP are presented for general informational purposes only and are not intended to promote any product or state any specific claims for the product or imply that any product is safe or effective, including for any specific indication.

EpiEP’s products discussed and represented on the Site are not for commercial sale in any country in which the products have not been approved or cleared for sale in accordance with applicable local law. Certain of the company’s products are investigational devices and use is limited by applicable law to investigational use only. Medical devices must withstand regulatory review by the appropriate government authorities before they become commercially or clinically available in any specific country. The requirements to obtain approval or clearance differ throughout the world.

We make no representations that the products are now, or will ever become, available for use in any specific country or for any specific indication.

No Advice Provided

EpiEP does not intend for you to consider any of the information contained or referenced in this Site to be a solicitation or promotion for any product or service or as medical advice for the treatment of any illness or disease, and you should not use it for these purposes. Patients should consult with their treating physicians if medical advice is needed. Developments in medical research may impact the information that appears on the Site. No assurances are provided that the information contained on the Site will always be accurate or complete or that it will include the most recent findings or developments with respect to any particular material.

Disclaimer of Warranty


Limitation of Liability


Transmissions to this Site; Feedback

Any material, information or ideas you transmit to or post on or through this Site by any means will be treated as non-confidential and non-proprietary, and may be disseminated or used by EpiEP or its affiliates for any purpose whatsoever, including, but not limited to, developing, manufacturing and marketing products. To the extent that the foregoing provisions conflict with the terms of a written agreement between you and EpiEP, the terms of such agreement will control.

This Site may contain hyperlinks to certain third party web sites. We do not maintain or control such third party sites and any hyperlinks are provided solely as a convenience to you. By providing these links, we are not endorsing, adopting or agreeing with any of the content of the linked sites. The content of linked web sites is not part of this Site. We do not review or control the content of third party sites. We expressly disclaim any responsibility for the content of any third party sites linked to this Site. We urge you to use discretion when you access any third party sites linked to our site.


The Terms of Use and our Privacy Statement shall constitute the entire agreement between you and EpiEP regarding your use of and access to the Site and shall supersede any and all prior terms of use or agreements between you and EpiEP relating to the use of the Site.
No waiver of any breach of the Terms of Use, whether by conduct or otherwise, shall be deemed to be a waiver of another or subsequent breach of the Terms of Use. Failure of EpiEP to enforce any breach of the Terms of Use shall not be deemed to be a waiver of EpiEP’s right to subsequently enforce any breach thereafter.

If any term or condition of the Terms of Use shall be held illegal, invalid or unenforceable, the remaining terms and conditions of the Terms of Use shall not be affected thereby and such terms and conditions shall be valid and enforceable to the fullest extent permitted by law. This Site is controlled and operated by EpiEP from the United States.

EpiEP makes no representation that materials in the Site are appropriate or available for use in other locations, and access to them from territories where their contents are illegal is prohibited. Those who choose to access this Site from other locations do so on their own initiative and are responsible for compliance with applicable local laws.

Any claim relating to, and the use of, this Site and the materials contained herein shall be governed by the laws of the United States of America and state of Massachusetts. By accessing or using this Site, you consent to exclusive jurisdiction and venue in such federal and state courts in the State of Massachusetts.

EpiEP may terminate or suspend the Site or your access to the Site at any time without notice, including upon any breach by you of any provision of these Terms of Use.